Global Recombinant Therapeutic Protein Market Growth 2024-2030

Publication ID:

LPI12251607

Publication Date:

December 30, 2024

Pages:

114

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Recombinant Therapeutic Protein market size was valued at US$ million in 2023. With growing demand in downstream market, the Recombinant Therapeutic Protein is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global Recombinant Therapeutic Protein market. Recombinant Therapeutic Protein are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Recombinant Therapeutic Protein. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Recombinant Therapeutic Protein market.
Recombinant Therapeutic Protein are produced by using a technique called recombinant DNA or recombinant RNA to produce proteins. The method can be divided into in vitro method and in vivo method. Both approaches are premised on the use of genetic recombination techniques to obtain recombinant vectors attached to gene fragments that can be translated into target proteins and then transferred to host cells that can express target proteins to express specific recombinant governance protein molecules.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Recombinant Therapeutic Protein market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Recombinant Therapeutic Protein market. It may include historical data, market segmentation by Type (e.g., Recombinant Human Collage, Recombinant Human Serum Albumin), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Recombinant Therapeutic Protein market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Recombinant Therapeutic Protein market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Recombinant Therapeutic Protein industry. This include advancements in Recombinant Therapeutic Protein technology, Recombinant Therapeutic Protein new entrants, Recombinant Therapeutic Protein new investment, and other innovations that are shaping the future of Recombinant Therapeutic Protein.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Recombinant Therapeutic Protein market. It includes factors influencing customer ' purchasing decisions, preferences for Recombinant Therapeutic Protein product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Recombinant Therapeutic Protein market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Recombinant Therapeutic Protein market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Recombinant Therapeutic Protein market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Recombinant Therapeutic Protein industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Recombinant Therapeutic Protein market.
Market Segmentation:
Recombinant Therapeutic Protein market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Segmentation by type
Recombinant Human Collage
Recombinant Human Serum Albumin
Segmentation by application
Medicine
Scientific Research
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Boehringer Ingelheim
Bristol-Myers Squibb
Celldex Therapeutics
Eli Liily
GlaxoSmithKline
Merck
Novartis
Regeneron Pharmaceuticals
Roche
Takeda
Key Questions Addressed in this Report
What is the 10-year outlook for the global Recombinant Therapeutic Protein market?
What factors are driving Recombinant Therapeutic Protein market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Recombinant Therapeutic Protein market opportunities vary by end market size?
How does Recombinant Therapeutic Protein break out type, application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Recombinant Therapeutic Protein Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Recombinant Therapeutic Protein by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Recombinant Therapeutic Protein by Country/Region, 2019, 2023 & 2030
2.2 Recombinant Therapeutic Protein Segment by Type
2.2.1 Recombinant Human Collage
2.2.2 Recombinant Human Serum Albumin
2.3 Recombinant Therapeutic Protein Sales by Type
2.3.1 Global Recombinant Therapeutic Protein Sales Market Share by Type (2019-2024)
2.3.2 Global Recombinant Therapeutic Protein Revenue and Market Share by Type (2019-2024)
2.3.3 Global Recombinant Therapeutic Protein Sale Price by Type (2019-2024)
2.4 Recombinant Therapeutic Protein Segment by Application
2.4.1 Medicine
2.4.2 Scientific Research
2.4.3 Others
2.5 Recombinant Therapeutic Protein Sales by Application
2.5.1 Global Recombinant Therapeutic Protein Sale Market Share by Application (2019-2024)
2.5.2 Global Recombinant Therapeutic Protein Revenue and Market Share by Application (2019-2024)
2.5.3 Global Recombinant Therapeutic Protein Sale Price by Application (2019-2024)
3 Global Recombinant Therapeutic Protein by Company
3.1 Global Recombinant Therapeutic Protein Breakdown Data by Company
3.1.1 Global Recombinant Therapeutic Protein Annual Sales by Company (2019-2024)
3.1.2 Global Recombinant Therapeutic Protein Sales Market Share by Company (2019-2024)
3.2 Global Recombinant Therapeutic Protein Annual Revenue by Company (2019-2024)
3.2.1 Global Recombinant Therapeutic Protein Revenue by Company (2019-2024)
3.2.2 Global Recombinant Therapeutic Protein Revenue Market Share by Company (2019-2024)
3.3 Global Recombinant Therapeutic Protein Sale Price by Company
3.4 Key Manufacturers Recombinant Therapeutic Protein Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Recombinant Therapeutic Protein Product Location Distribution
3.4.2 Players Recombinant Therapeutic Protein Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Recombinant Therapeutic Protein by Geographic Region
4.1 World Historic Recombinant Therapeutic Protein Market Size by Geographic Region (2019-2024)
4.1.1 Global Recombinant Therapeutic Protein Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Recombinant Therapeutic Protein Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Recombinant Therapeutic Protein Market Size by Country/Region (2019-2024)
4.2.1 Global Recombinant Therapeutic Protein Annual Sales by Country/Region (2019-2024)
4.2.2 Global Recombinant Therapeutic Protein Annual Revenue by Country/Region (2019-2024)
4.3 Americas Recombinant Therapeutic Protein Sales Growth
4.4 APAC Recombinant Therapeutic Protein Sales Growth
4.5 Europe Recombinant Therapeutic Protein Sales Growth
4.6 Middle East & Africa Recombinant Therapeutic Protein Sales Growth
5 Americas
5.1 Americas Recombinant Therapeutic Protein Sales by Country
5.1.1 Americas Recombinant Therapeutic Protein Sales by Country (2019-2024)
5.1.2 Americas Recombinant Therapeutic Protein Revenue by Country (2019-2024)
5.2 Americas Recombinant Therapeutic Protein Sales by Type
5.3 Americas Recombinant Therapeutic Protein Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Recombinant Therapeutic Protein Sales by Region
6.1.1 APAC Recombinant Therapeutic Protein Sales by Region (2019-2024)
6.1.2 APAC Recombinant Therapeutic Protein Revenue by Region (2019-2024)
6.2 APAC Recombinant Therapeutic Protein Sales by Type
6.3 APAC Recombinant Therapeutic Protein Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Recombinant Therapeutic Protein by Country
7.1.1 Europe Recombinant Therapeutic Protein Sales by Country (2019-2024)
7.1.2 Europe Recombinant Therapeutic Protein Revenue by Country (2019-2024)
7.2 Europe Recombinant Therapeutic Protein Sales by Type
7.3 Europe Recombinant Therapeutic Protein Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Recombinant Therapeutic Protein by Country
8.1.1 Middle East & Africa Recombinant Therapeutic Protein Sales by Country (2019-2024)
8.1.2 Middle East & Africa Recombinant Therapeutic Protein Revenue by Country (2019-2024)
8.2 Middle East & Africa Recombinant Therapeutic Protein Sales by Type
8.3 Middle East & Africa Recombinant Therapeutic Protein Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Therapeutic Protein
10.3 Manufacturing Process Analysis of Recombinant Therapeutic Protein
10.4 Industry Chain Structure of Recombinant Therapeutic Protein
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Recombinant Therapeutic Protein Distributors
11.3 Recombinant Therapeutic Protein Customer
12 World Forecast Review for Recombinant Therapeutic Protein by Geographic Region
12.1 Global Recombinant Therapeutic Protein Market Size Forecast by Region
12.1.1 Global Recombinant Therapeutic Protein Forecast by Region (2025-2030)
12.1.2 Global Recombinant Therapeutic Protein Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Recombinant Therapeutic Protein Forecast by Type
12.7 Global Recombinant Therapeutic Protein Forecast by Application
13 Key Players Analysis
13.1 Boehringer Ingelheim
13.1.1 Boehringer Ingelheim Company Information
13.1.2 Boehringer Ingelheim Recombinant Therapeutic Protein Product Portfolios and Specifications
13.1.3 Boehringer Ingelheim Recombinant Therapeutic Protein Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Boehringer Ingelheim Main Business Overview
13.1.5 Boehringer Ingelheim Latest Developments
13.2 Bristol-Myers Squibb
13.2.1 Bristol-Myers Squibb Company Information
13.2.2 Bristol-Myers Squibb Recombinant Therapeutic Protein Product Portfolios and Specifications
13.2.3 Bristol-Myers Squibb Recombinant Therapeutic Protein Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Bristol-Myers Squibb Main Business Overview
13.2.5 Bristol-Myers Squibb Latest Developments
13.3 Celldex Therapeutics
13.3.1 Celldex Therapeutics Company Information
13.3.2 Celldex Therapeutics Recombinant Therapeutic Protein Product Portfolios and Specifications
13.3.3 Celldex Therapeutics Recombinant Therapeutic Protein Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 Celldex Therapeutics Main Business Overview
13.3.5 Celldex Therapeutics Latest Developments
13.4 Eli Liily
13.4.1 Eli Liily Company Information
13.4.2 Eli Liily Recombinant Therapeutic Protein Product Portfolios and Specifications
13.4.3 Eli Liily Recombinant Therapeutic Protein Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Eli Liily Main Business Overview
13.4.5 Eli Liily Latest Developments
13.5 GlaxoSmithKline
13.5.1 GlaxoSmithKline Company Information
13.5.2 GlaxoSmithKline Recombinant Therapeutic Protein Product Portfolios and Specifications
13.5.3 GlaxoSmithKline Recombinant Therapeutic Protein Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 GlaxoSmithKline Main Business Overview
13.5.5 GlaxoSmithKline Latest Developments
13.6 Merck
13.6.1 Merck Company Information
13.6.2 Merck Recombinant Therapeutic Protein Product Portfolios and Specifications
13.6.3 Merck Recombinant Therapeutic Protein Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Merck Main Business Overview
13.6.5 Merck Latest Developments
13.7 Novartis
13.7.1 Novartis Company Information
13.7.2 Novartis Recombinant Therapeutic Protein Product Portfolios and Specifications
13.7.3 Novartis Recombinant Therapeutic Protein Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Novartis Main Business Overview
13.7.5 Novartis Latest Developments
13.8 Regeneron Pharmaceuticals
13.8.1 Regeneron Pharmaceuticals Company Information
13.8.2 Regeneron Pharmaceuticals Recombinant Therapeutic Protein Product Portfolios and Specifications
13.8.3 Regeneron Pharmaceuticals Recombinant Therapeutic Protein Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Regeneron Pharmaceuticals Main Business Overview
13.8.5 Regeneron Pharmaceuticals Latest Developments
13.9 Roche
13.9.1 Roche Company Information
13.9.2 Roche Recombinant Therapeutic Protein Product Portfolios and Specifications
13.9.3 Roche Recombinant Therapeutic Protein Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Roche Main Business Overview
13.9.5 Roche Latest Developments
13.10 Takeda
13.10.1 Takeda Company Information
13.10.2 Takeda Recombinant Therapeutic Protein Product Portfolios and Specifications
13.10.3 Takeda Recombinant Therapeutic Protein Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Takeda Main Business Overview
13.10.5 Takeda Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂